Thursday, May 23, 2013
Publication and contact
Integrin b1 (CD29)
In vitro and mouse studies suggest CD29 inhibitors could
help treat Avastin
glioblastoma multiforme (GBM). In cultures of Avastin-treated or
Avastin-resistant primary GBM cells, CD29 expression was greater than that in
untreated or bevacizumab-sensitive cells. In mice with Avastin-resistant
orthotopic xenograft GBM tumors, an anti-CD29 antibody (OS2966)
decreased tumor growth compared with an inactive control IgG. In mice with
Avastin-sensitive xenograft GBM tumors, OS2966 plus low-dose Avastin
decreased tumor growth compared with low-dose Avastin plus control IgG.
Ongoing work by OncoSynergy
Inc. includes testing OS2966 in models of recurrent GBM and
and its Genentech
Inc. and Chugai Pharmaceutical
Co. Ltd. units market Avastin, a humanized mAb against VEGF,
to treat brain, breast and colorectal cancers.
Published online May 23, 2013
Patented by The
Regents of the University of California; licensed to
OncoSynergy; available for partnering
Carbonell, W.S. et al.
Cancer Res.; published online May 3, 2013;
Contact: W. Shawn Carbonell, University of California, San Francisco,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]